HighPoint Advisor Group’s Syndax Pharmaceuticals SNDX Stock Holding History

HighPoint Advisor Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,610	Closed	-$73K	–	460
2019 Q3	$73K	Hold	10,610	–	–	0.02%	473
2019 Q2	$96K	Hold	10,610	–	–	0.02%	470
2019 Q1	$82K	Hold	10,610	–	–	0.02%	331
2018 Q4	$66K	Sell	10,610 -2,300	-18%	-$12.6K	0.02%	312
2018 Q3	$88K	Buy	+12,910	New	+$92K	0.02%	342
2018 Q1	–	Sell	-11,110	Closed	-$102K	–	322
2017 Q4	$102K	Buy	+11,110	New	+$110K	0.03%	292

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HighPoint Advisor Group's SNDX Position: Q4 2019 in Review

HighPoint Advisor Group sold out of Syndax Pharmaceuticals (SNDX) in Q4 2019, closing a stake of 10,610 shares — an estimated $73K sold.

HighPoint Advisor Group first reported a position in SNDX in Q4 2017 and held it in 6 quarters. The position peaked at $102K in Q4 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q4 2019.

HighPoint Advisor Group reported no remaining Syndax Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
HighPoint Advisor Group sold 10,610 Syndax Pharmaceuticals shares in Q4 2019, an estimated $73K.
HighPoint Advisor Group first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 6 quarters.
HighPoint Advisor Group's Syndax Pharmaceuticals position peaked at $102K in Q4 2017.
72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2019.

Based on HighPoint Advisor Group's 13F filing for Q4 2019, filed 13 Feb 2020.